Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study
Open accessThe DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Depression among methamphetamine users is more prevalent in females than males, but gender-specific treatment options for this comorbidity have not been described. Reduced brain phosphocreatine levels have been shown to be lower in female methamphetamine users compared to males, and, of relevance, studies have demonstrated an association between treatment-resistant depression and reduced brain phosphocreatine concentrations. The nutritional supplement creatine monohydrate has been reported to reduce symptoms of depression in female adolescents and adults taking antidepressants, as well as to increase brain phosphocreatine in healthy volunteers. Therefore, the purpose of this pilot study was to investigate creatine monohydrate as a treatment for depression in female methamphetamine users. METHODS: Fourteen females with depression and comorbid methamphetamine dependence were enrolled in an 8-week open label trial of 5 g of daily creatine monohydrate and of these 14, 11 females completed the study. Depression was measured using the Hamilton Depression Rating Scale (HAMD) and brain phosphocreatine levels were measured using phosphorus magnetic resonance spectroscopy pre- and post-creatine treatment. Secondary outcome measures included anxiety symptoms, measured with the Beck Anxiety Inventory (BAI), as well as methamphetamine use, monitored by twice weekly urine drug screens and self-reported use. RESULTS: The results of a linear mixed effects repeated measures model showed significantly reduced HAMD and BAI scores as early as week 2 when compared to baseline scores. This improvement was maintained through study completion. Brain phosphocreatine concentrations were higher at the second phosphorus magnetic resonance spectroscopy scan compared to the baseline scan; Mbaseline = 0.223 (SD = 0.013) vs. Mpost-treatment = 0.233 (SD = 0.009), t (9) = 2.905, p <.01, suggesting that creatine increased phosphocreatine levels. Also, a reduction in methamphetamine positive urine drug screens of greater than 50% was observed by week 6. Finally, creatine was well tolerated and adverse events that were related to gastrointestinal symptoms and muscle cramping were determined as possibly related to creatine. CONCLUSIONS: The current study suggests that creatine treatment may be a promising therapeutic approach for females with depression and comorbid methamphetamine dependence. This study is registered on clinicaltrials.gov (NCT01514630).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increasing creatine concentrations in the brain as a result of supplementation, particularly in females, may support the reported benefits of reducing symptoms of depression [171, 172] and ameliorating the effects of traumatic brain injury [12, 22].”
From Common questions and misconceptions about creatine supplementation: what does the scientific evidence really show? (2021) · cites this paper as [172]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“When combined with regular antidepressant use, 8-weeks of CrM supplementation reduced depressive symptoms in female adolescents and adults with major depression [86,87,88].”
From Creatine supplementation in women's health: a lifespan perspective (2021) · cites this paper as [86]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
An inventory for measuring clinical anxiety: Psychometric properties.
Beck, A. T., Epstein, N., Brown, G., & Steer, R. A. (1988) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.56.6.893 · Cited by 14,407
The American Journal of Physiology
(1899) · The American Naturalist · doi:10.1086/277182 · Cited by 5,654
Morbidity and Mortality Weekly Report
(2011) · Wilderness & Environmental Medicine · doi:10.1016/j.wem.2010.11.007 · Cited by 3,423
Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, S. P., Dufour, M. C., Compton, W., Pickering, R. P., & Kaplan, K. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.8.807 · Cited by 2,889
The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence
(1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.11.1259 · Cited by 2,538
The role and interpretation of pilot studies in clinical research
Leon, A. C., Davis, L. L., & Kraemer, H. C. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.10.008 · Cited by 1,917
The Hawthorne Effect: a randomised, controlled trial
McCarney, R., Warner, J., Iliffe, S., van Haselen, R., Griffin, M., & Fisher, P. (2007) · BMC Medical Research Methodology · doi:10.1186/1471-2288-7-30 · Cited by 1,715
Improved Method for Accurate and Efficient Quantification of MRS Data with Use of Prior Knowledge
Vanhamme, L., van den Boogaart, A., & Van Huffel, S. (1997) · Journal of Magnetic Resonance · doi:10.1006/jmre.1997.1244 · Cited by 1,627
Journal of Strength and Conditioning Research: Among the Best News You Can Use
Koziris, L. P. (2003) · Strength and Conditioning Journal · doi:10.1519/00126548-200302000-00014 · Cited by 1,579
Research works printed but not linked: 7
- Bizzarini E., 2004, Journal of Sports Medicine and Physical Fitness, 44, 411
- 10.1189/1550-2783-9-99 · doi:10.1189/1550-2783-9-99
- 10.1097/jan.000000000000058 · doi:10.1097/jan.000000000000058
- Jou S.H., 2009, Chang Gung Medical Journal, 32, 370
- 10.1016/j.psychires.2010.10.008 · doi:10.1016/j.psychires.2010.10.008
- Lukaszuk J.M., 2005, Journal of Strength and Conditioning Research, 19, 735
- McKetin R., 2011, Medical Journal of Australia, 195, S51
Cited by
Antonio, J., Candow, D. G., Forbes, S. C., Gualano, B., Jagim, A. R., Kreider, R. B., Rawson, E. S., Smith-Ryan, A. E., VanDusseldorp, T. A., Willoughby, D. S., et al. (2021) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-021-00412-w · Cited by 345
“Increasing creatine concentrations in the brain as a result of supplementation, particularly in females, may support the reported benefits of reducing symptoms of depression [171, 172] and ameliorating the effects of traumatic brain injury [12, 22].”
BackgroundEffects of creatine supplementation on brain function and health
Forbes, S. C., Cordingley, D. M., Cornish, S. M., Gualano, B., Roschel, H., Ostojic, S. M., Rawson, E. S., Roy, B. D., Prokopidis, K., Giannos, P., et al. (2022) · Nutrients · doi:10.3390/nu14050921 · Cited by 145
Dolan, E., Gualano, B., & Rawson, E. S. (2019) · European Journal of Sport Science · doi:10.1080/17461391.2018.1500644 · Cited by 171
Living High and Feeling Low: Altitude, Suicide, and Depression
Kious, B. M., Kondo, D. G., & Renshaw, P. F. (2018) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000158 · Cited by 143
Self-citationCreatine supplementation in the aging population: effects on skeletal muscle, bone and brain
Gualano, B., Rawson, E. S., Candow, D. G., & Chilibeck, P. D. (2016) · Amino Acids · doi:10.1007/s00726-016-2239-7 · Cited by 133
Metadata
- Authors
- Hellem, T. L., Sung, Y.-H., Shi, X.-F., Pett, M. A., Latendresse, G., Morgan, J., Huber, R. S., Kuykendall, D., Lundberg, K. J., & Renshaw, P. F.
- Affiliations
- University of Utah (US)
- Corresponding author
- Hellem, Tracy L.
- ORCID
- Venue
- Journal of Dual Diagnosis
- Publisher
- Informa UK Limited
- Published
- 2015-10-02
- Volume
- 11
- Issue
- 3-4
- Pages
- 189-202
- ISSN
- 1550-4263 (ISSN-L)
- 1550-4271
- PMC
- PMC4684979
- OpenAlex
- W2143531665
- Cited by
- 49
- References
- 101
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 6 · 2023: 5 · 2022: 2 · 2021: 4 · 2020: 6 · 2019: 5 · 2018: 5 · 2017: 2 · 2016: 3 · 2015: 1
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Dual Diagnosis (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Gazi Üniversitesi
- National Institutes of Health (5ul1tr001067-05)
- National Institute of Mental Health (R33MH096858)
- National Institute on Drug Abuse (K05DA031247, R36DA036767)
- National Center for Advancing Translational Sciences (UL1-TR001067)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- creatine monohydrate, depression, methamphetamine dependence, treatment-resistant depression, anxiety symptoms, phosphorus magnetic resonance spectroscopy, dietary supplementation, gender differences in depression
- MeSH terms
- Adult, Antidepressive Agents, Brain, Creatine, Depressive Disorder, Female, Humans, Methamphetamine, Middle Aged, Magnetic Resonance Spectroscopy, Phosphocreatine, Pilot Projects, Treatment Outcome, Diagnosis, Dual (Psychiatry), Amphetamine-Related Disorders, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study. https://app.cochat.ai/papers/10.1080/15504263.2015.1100471
- The paper
- Hellem, T. L., Sung, Y.-H., Shi, X.-F., Pett, M. A., Latendresse, G., Morgan, J., Huber, R. S., Kuykendall, D., Lundberg, K. J., & Renshaw, P. F. (2015). Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study. Journal of Dual Diagnosis. https://doi.org/10.1080/15504263.2015.1100471
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.